Latest news and press releases about Inventiva S.A. (IVA): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Inventiva S.A. is a biopharmaceutical company currently in its clinical development phase, specializing in the creation of orally administered small molecule therapeutics. The firm primarily targets serious conditions such as non-alcoholic steatohepatitis (NASH), various forms of mucopolysaccharidoses (MPS), and other significant diseases.
Price
| Price | $3.79 |
| Market Cap | $197M |
| Exchange | NASDAQ |
| Country | FR |
Valuation Ratios
| Price / Book | -71.60 |
| EV / EBITDA | -5.72 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | 1870.38% |
| Return on Invested Capital | -66.18% |
| Return on Assets | -141.93% |
| Gross Margin | 35.07% |
| Operating Margin | -3037.30% |
| Net Margin | -7899.58% |
Related companies: AVTX · CRBU · ENTA · EPRX · GNFT · IVVD · NAUT
Explore sector: Healthcare · Biotechnology
More sections of IVA: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks